Neuroleptic Malignant Syndrome Associated with Quetiapine

Natalie Roy, Paula L. Diaz, John Howard

Abstract


INTRODUCTION

Neuroleptic malignant syndrome is a rare adverse effect of antipsychotic agents. The most common signs and symptoms are hyperthermia, muscle rigidity, changes in mental status, and autonomic instability.1 The prevalence of neuroleptic malignant syndrome in association with the use of typical antipsychotics is estimated at 0.5% to 1%.1 Atypical antipsychotics such as quetiapine have greater affinity for serotonin 5-HT2A receptors than for dopamine D2 receptors. Therefore, it is believed that atypical antipsychotics are less likely to cause this condition. This article describes a patient treated with quetiapine who presented with biochemical and clinical evidence of neuroleptic malignant syndrome.


Full Text:

PDF


DOI: http://dx.doi.org/10.4212/cjhp.v53i5.773

ISSN 1920-2903 (Online)
Copyright © 2019 Canadian Society of Hospital Pharmacists